FOXP3 and small cell lung carcinoma: High FOXP3 expression showed longer relapse-free survival than the low-level group of SCLC (41 months, 95% CI 26.937 to 55.463, vs. 14 months, 95% CI 8.133 to 19.867; p = 0.008) [68].